Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:45am, Thursday, 07'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now
01:46pm, Tuesday, 05'th Nov 2024
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
01:21pm, Tuesday, 05'th Nov 2024
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
12:41pm, Tuesday, 05'th Nov 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best
Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know
10:22am, Monday, 04'th Nov 2024
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
3 Magnificent Stocks Under $100 to Buy in November
06:41am, Sunday, 03'rd Nov 2024
The price could be right for these stocks.
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
09:55am, Thursday, 31'st Oct 2024
Exelixis's Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. EXEL plans to diversify its oncology portfolio by launching one new indication for Zan
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
11:10am, Wednesday, 30'th Oct 2024
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
10:31pm, Tuesday, 29'th Oct 2024
Exelixis, Inc. (NASDAQ:EXEL ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 29'th Oct 2024
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
06:20pm, Tuesday, 29'th Oct 2024
Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 24'th Oct 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
10:11am, Thursday, 24'th Oct 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, B
Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy
01:01pm, Wednesday, 23'rd Oct 2024
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
1 No-Brainer Stock to Buy With $40
09:53am, Wednesday, 23'rd Oct 2024
The midcap biotech just became an even better buy.
